The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

Ultrasound imaging is a non-invasive, non-radioactive, and low cost technology for diagnosis and identification of implantable medical devices in real time. Developing new ultrasound activated coatings is important to broaden the utility of in vivo marking by ultrasound imaging. Ultrasound responsive macro-phase segregated micro-composite thin films were developed to be coated on medical devices composed of multiple materials and with multiple shapes and varying surface area. The macro-phase segregated in films having silica micro-shells in polycyanoacrylate produces strong color Doppler signals with the use of a standard clinical ultrasound transducer. Electron microscopy showed a macro-phase separation during slow curing of the cyanoacrylate adhesive, as air-filled silica micro-shells were driven to the surface of the film. The air sealed in the hollow space of the silica shells acted as an ultrasound contrast agent and echo decorrelation of air exposed to ultrasound waves produces color Doppler signals.

Ultrasound imaging is a non-invasive, non-radioactive, and low cost technology for diagnosis and identification of implantable medical devices in real time. Developing new ultrasound activated coatings is important to broaden the utility of in vivo marking by ultrasound imaging. Ultrasound responsive macro-phase segregated micro-composite thin films were developed to be coated on medical devices composed of multiple materials and with multiple shapes and varying surface area. The macro-phase segregated in films having silica micro-shells in polycyanoacrylate produces strong color Doppler signals with the use of a standard clinical ultrasound transducer. Electron microscopy showed a macro-phase separation during slow curing of the cyanoacrylate adhesive, as air-filled silica micro-shells were driven to the surface of the film. The air sealed in the hollow space of the silica shells acted as an ultrasound contrast agent and echo decorrelation of air exposed to ultrasound waves produces color Doppler signals.

A malleable polysaccharide soft tissue filler for filling tissue cavities or voids such as those resulting from tumor removal or other tissue resection. The soft tissue filler includes a first cross-linking polysaccharide, preferably a beta-D glucan, and a second cross-linking polysaccharide. The soft tissue filler is both porous and malleable and can be formed to accommodate the tissue cavity or void. The soft tissue filler can include an embedded marker for locating on medical imaging. Methods of making the soft tissue filler including lyophilizing an aqueous polysaccharide suspension are disclosed. The second cross-linking polysaccharide provides for increased structural integrity in a high-porosity and malleable soft tissue filler in which the respective cross-linking polysaccharides synergistically provide structural scaffolding for one another. Methods of use are also disclosed.

A malleable polysaccharide soft tissue filler for filling tissue cavities or voids such as those resulting from tumor removal or other tissue resection. The soft tissue filler includes a first cross-linking polysaccharide, preferably a beta-D glucan, and a second cross-linking polysaccharide. The soft tissue filler is both porous and malleable and can be formed to accommodate the tissue cavity or void. The soft tissue filler can include an embedded marker for locating on medical imaging. Methods of making the soft tissue filler including lyophilizing an aqueous polysaccharide suspension are disclosed. The second cross-linking polysaccharide provides for increased structural integrity in a high-porosity and malleable soft tissue filler in which the respective cross-linking polysaccharides synergistically provide structural scaffolding for one another. Methods of use are also disclosed.

Provided are superabsorbent materials composed of one or more water-soluble polysaccharides, such as gelling polysaccharides and gelling-compatible polysaccharides, and one or more insoluble fibers. The disclosed superabsorbent materials have a porous network structure and highly stable gelling properties as well as high absorption ratio and volume expansion capacity upon hydration or rehydration. Also provided are methods for preparing such superabsorbent materials and uses thereof.

Provided are superabsorbent materials composed of one or more water-soluble polysaccharides, such as gelling polysaccharides and gelling-compatible polysaccharides, and one or more insoluble fibers. The disclosed superabsorbent materials have a porous network structure and highly stable gelling properties as well as high absorption ratio and volume expansion capacity upon hydration or rehydration. Also provided are methods for preparing such superabsorbent materials and uses thereof.

The present invention relates to a use of an agarobiose or agarooligosaccharides having anticariogenic activity. More specifically, a lower concentration of agarobiose or agarooligosaccharides than the concentration of xylitol suppresses the growth of Streptococcus mutans and suppresses acid production, and thus can be used for anti-cariogenic purposes.

The present invention relates to a use of an agarobiose or agarooligosaccharides having anticariogenic activity. More specifically, a lower concentration of agarobiose or agarooligosaccharides than the concentration of xylitol suppresses the growth of Streptococcus mutans and suppresses acid production, and thus can be used for anti-cariogenic purposes.

The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.